
Akamis Bio Reports Promising Early Phase 1b FORTRESS Results for NG-350A in MMR-Proficient Locally Advanced Rectal Cancer
Akamis Bio Reports Promising Early Findings from Phase 1b FORTRESS Trial of NG-350A in MMR-Proficient Locally Advanced Rectal Cancer Akamis Bio, a biotechnology company focused on transforming the treatment landscape…












